

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **BOOK CLOSURE PERIOD FOR THE EXTRAORDINARY GENERAL MEETING**

The board (the “**Board**”) of directors (“**Directors**”) of Ascletis Pharma Inc. (the “**Company**”, and its subsidiaries, the “**Group**”) hereby announces that for the purpose of determining the entitlements of the shareholders of the Company (the “**Shareholders**”) to attend and vote at a proposed extraordinary general meeting (the “**EGM**”) of the Company to be convened on Monday, February 3, 2025, the register of members will be closed from Tuesday, January 28, 2025 to Monday, February 3, 2025, both days inclusive, during which period no transfer of shares will be registered.

In order to qualify to attend and vote at the EGM, all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Monday, January 27, 2025.

The Company will provide additional details of the EGM and notify Shareholders of the publication of the circular, the notice of the EGM, as well as the related proxy forms in due course.

By order of the Board  
**Ascletis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People’s Republic of China  
January 14, 2025

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*